Cravens & Co Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $298K | Buy |
7,759
+170
| +2% | +$6.53K | 0.22% | 47 |
|
|
2025
Q1 | $294K | Buy |
+7,589
| New | +$294K | 0.23% | 48 |
|
|
2024
Q4 | – | Sell |
-7,459
| Closed | -$305K | – | 65 |
|
|
2024
Q3 | $305K | Sell |
7,459
-881
| -11% | -$36K | 0.24% | 51 |
|
|
2024
Q2 | $321K | Sell |
8,340
-197
| -2% | -$7.59K | 0.24% | 57 |
|
|
2024
Q1 | $366K | Sell |
8,537
-382
| -4% | -$16.4K | 0.3% | 54 |
|
|
2023
Q4 | $331K | Sell |
8,919
-315
| -3% | -$11.7K | 0.29% | 58 |
|
|
2023
Q3 | $335K | Sell |
9,234
-99
| -1% | -$3.59K | 0.31% | 58 |
|
|
2023
Q2 | $333K | Sell |
9,333
-76
| -0.8% | -$2.71K | 0.31% | 56 |
|
|
2023
Q1 | $335K | Buy |
9,409
+3
| +0% | +$107 | 0.31% | 55 |
|
|
2022
Q4 | $331K | Buy |
+9,406
| New | +$331K | 0.31% | 59 |
|